Literature DB >> 1730594

Metabolism of 4'-azidothymidine. A compound with potent and selective activity against the human immunodeficiency virus.

M S Chen1, R T Suttmann, J C Wu, E J Prisbe.   

Abstract

4'-Azidothymidine (ADRT) is a novel nucleoside analog, that selectively inhibits human immunodeficiency virus replication in human lymphocytes. Unlike the dideoxyribonucleoside analogs and 3'-azido-2',3'-dideoxythymidine (AZT), ADRT retains the 3'-hydroxy group. The pathways of ADRT metabolism were elucidated by determining: (i) the kinetics of the interactions of ADRT and its metabolites with enzymes of thymidine metabolic pathways, (ii) the pool sizes of phosphorylated metabolites, and (iii) the nature of ADRT incorporation into human DNA. ADRT is not a substrate for thymidine phosphorylase, but is metabolized by kinases. Thymidine kinase phosphorylates ADRT to ADRT monophosphate (ADRT-MP). For this enzyme, ADRT has a Ki value of 5.2 microM, in comparison to a Km value of 0.7 microM for thymidine. The Km value of ADRT toward thymidine kinase is 8.3 microM and the rate of ADRT phosphorylation is 1.4% that of thymidine phosphorylation. ADRT-MP has a low affinity toward thymidylate kinase (a Ki value of 28.9 microM versus a Km value of 0.56 microM for thymidylate), and toward thymidylate synthase (a Ki value of 180 microM versus a Km value of 8 microM for deoxyuridylate). The results suggest that ADRT can be activated effectively by cellular kinases without significant interference of normal thymidine metabolism. In cultured human lymphocytes (A3.01, H9, and U937 cells), ADRT was phosphorylated efficiently to ADRT 5'-triphosphate (ADRT-TP), which is the major metabolite of ADRT. The intracellular concentrations of ADRT-TP ranged from 1 to 3.3 microM after 24 h of incubation with 2 microM of ADRT and the half-life of ADRT-TP varied from 3 to 6 h. Although ADRT-TP is a poor competitive inhibitor against dTTP toward DNA polymerases alpha and beta with Ki values of 62.5 and 150 microM, respectively. ADRT-MP was found to be internally incorporated into cellular DNA. The extent of ADRT-MP substitution for dTMP in DNA was 1 in 6979 for A3.01 cells incubated with 2.9 microM ADRT for 24 h. Internal incorporation of ADRT-MP contrasts with the mechanism of other 2',3'-dideoxynucleoside analogs (i.e. AZT, ddC, ddI, d4T...), which are DNA chain terminators. This finding indicates that a 3'-deoxy structure in a nucleoside analog is not a prerequisite for anti-human immunodeficiency virus activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730594

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase.

Authors:  Robert A Domaoal; Moira McMahon; Chloe L Thio; Christopher M Bailey; Julian Tirado-Rives; Aleksander Obikhod; Mervi Detorio; Kimberly L Rapp; Robert F Siliciano; Raymond F Schinazi; Karen S Anderson
Journal:  J Biol Chem       Date:  2007-10-25       Impact factor: 5.157

2.  Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.

Authors:  Takao Nitanda; Xin Wang; Hiroki Kumamoto; Kazuhiro Haraguchi; Hiromichi Tanaka; Yung-Chi Cheng; Masanori Baba
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation.

Authors:  X Xiong; J L Smith; M S Chen
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

4.  Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase.

Authors:  D B Mendel; T Cihlar; K Moon; M S Chen
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

5.  Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.

Authors:  Eleftherios Michailidis; Bruno Marchand; Eiichi N Kodama; Kamlendra Singh; Masao Matsuoka; Karen A Kirby; Emily M Ryan; Ali M Sawani; Eva Nagy; Noriyuki Ashida; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

6.  Biochemical basis for increased susceptibility to Cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity.

Authors:  D B Mendel; D B Barkhimer; M S Chen
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

7.  1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo.

Authors:  N Bischofberger; M J Hitchcock; M S Chen; D B Barkhimer; K C Cundy; K M Kent; S A Lacy; W A Lee; Z H Li; D B Mendel
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

8.  Fluorinated Nucleosides: Synthesis and Biological Implication.

Authors:  Peng Liu; Ashoke Sharon; Chung K Chu
Journal:  J Fluor Chem       Date:  2008-09       Impact factor: 2.050

9.  Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.

Authors:  Hirotomo Nakata; Masayuki Amano; Yasuhiro Koh; Eiichi Kodama; Guangwei Yang; Christopher M Bailey; Satoru Kohgo; Hiroyuki Hayakawa; Masao Matsuoka; Karen S Anderson; Yung-Chi Cheng; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2007-06-04       Impact factor: 5.191

Review 10.  The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold.

Authors:  Mary K Yates; Katherine L Seley-Radtke
Journal:  Antiviral Res       Date:  2018-12-08       Impact factor: 10.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.